Pfizer

New York, Washington D.C.
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Pfizer is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Pfizer embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.

View Full Corporate Bias Ratings Report

Board Bias

Expand Summary

CEO of Pfizer

Albert Bourla DVM Ph.D.

Albert Bourla DVM Ph.D.

Summary:

Headquartered in New York, Washington D.C., Pfizer is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Albert Bourla DVM Ph.D. serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $269,500 to Republican causes and $1,524,244 to Democratic causes. Under their tenure, Pfizer currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:

$269,500

$1,524,244

Republican

Democrat

China Risk Database

Expand Summary

Number of Facilities: 3

View Full China Report

Total Estimated Sanctions (3-year Avg.)

$407,386,695

Average Annual Revenue

Global

$60,935,333,333

China Revenue

1.38%

$838,000,000

Annual Average of Total Assets

Global

$170,285,333,333

China Assets

1.82%

$3,103,020,384

Shareholder Proposals

Expand Summary

Date
ESG Category
Proponent
Summary of ResolutionMgmt RecTotal Vote % in Favor
4/25/24The New York City Carpenters Pension FundAmend Director Resignation ProcessesAgainstN/A
4/25/24National Center for Public Policy ResearchPublish a Report on Corporate ContributionsAgainstN/A
4/25/24Kenneth SteinerIndependent Board ChairmanAgainstN/A
4/25/24Tara Health FoundationPolitical Contributions Congruency ReportAgainstN/A
4/27/23GovernanceKenneth SteinerIndependent Board ChairAgainst34.52%
4/27/23SocialTrinity HealthReport on Impact of Extended Patent Exclusivities on Product AccessAgainst29.67%
4/27/23GovernanceTara Health FoundationReport on Congruency of Political ContributionsAgainst13.88%
4/27/23SocialOxfam AmericaFeasibility Report for Transfer of Intellectual Properties to Potential COVID-19 vaccine manufacturersAgainst11.99%
4/27/23GovernanceJohn CheveddenRatification of Termination PayAgainst9.90%
4/28/22GovernanceSisters of St. FrancisReport on Board Oversight of Risks Related to Anticompetitive PracticesAgainst30.45%
4/28/22GovernanceJohn CheveddenAmend Proxy Access RightAgainst28.98%
4/28/22SocialOxfam America, Inc.Report on Feasibility of Technology Transfer to Boost COVID-19 Vaccine ProductionAgainst27.37%
4/28/22SocialNational Center for Public Policy ResearchReport on Congruency of Political Election Expenditures with Company Values and PoliciesAgainst10.41%
4/28/22SocialThe Shareholder CommonsReport on Public Health Costs of Limited Sharing of Vaccine TechnologyAgainst8.71%
Generate Reports
Clear
Toast